articleTop 1% cited

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

The Lancet Oncology · 2010 · Vol. 11(11) · pp. 1029–1035

François‐Xavier Mahon✉(Inserm)Delphine Réa(Hôpital Saint-Louis)Joëlle Guilhot(Inserm)François Guilhot(Centre Hospitalier Universitaire de Poitiers)Françoise Huguet(Hôpital Purpan)Franck E. Nicolini(Hôpital Edouard Herriot)Laurence Legros(Centre Hospitalier Universitaire de Nice)Aude Charbonnier(Institut Paoli-Calmettes)Agnès Guerci(Centre Hospitalier Régional et Universitaire de Nancy)Bruno Varet(Hôpital Necker-Enfants Malades)Gabriel Étienne(Institut Bergonié)Josy Reiffers(Institut Bergonié)Philippe Rousselot(Inserm)

View via DOI Publisher page

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Chronic Lymphocytic Leukemia ResearchMedicineImatinibDiscontinuationInternal medicineImatinib mesylateInterim analysisProspective cohort studySurgeryClinical trialMyeloid leukemia

MeSH terms

Imatinib MesylateAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Administration ScheduleFemaleFranceHumansMaleMiddle AgedPiperazinesProspective StudiesPyrimidines

Funding

Centre Hospitalier Universitaire de Bordeaux

Citations

1,530

FWCI

57.56

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Blood · 2013 · 1,979 citations

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Leukemia · 2012 · 437 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.